Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: A retrospective analysis

Annals of Oncology

Volumn 18, Issue 12, 2007, Pages 1995-1999

  Gallagher, D J ^a   Capanu, M ^a   Raggio, G ^a   Kemeny, Nancy ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Colorectal cancer; Hepatic arterial infusion; Irinotecan; Metastatic; Oxaliplatin

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DEXAMETHASONE; FLOXURIDINE; HEPARIN; IRINOTECAN; OXALIPLATIN;

ABDOMINAL BLEEDING; ADENOCARCINOMA; ADULT; AGED; ARTERY INJURY; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; COLORECTAL SURGERY; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG WITHDRAWAL; DUODENAL ULCER BLEEDING; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEPATIC ARTERY; HUMAN; INOPERABLE CANCER; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER RESECTION; MALE; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; RETROSPECTIVE STUDIES;

EID: 37349026722     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm405     Document Type: Article

References (16)

1. Jewel A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J Clin 2004; 54: 8-29.
2. Fong Y, Cohen AM, Fortner JG et al. Liver resection for colorectal metastases. J Clin Onool 1997; 15: 938-946.
3. Toumigand C, Andre T, Achille E et al. Folfiri followed by Folfox 6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
4. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
5. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colon cancer. N Engl J Mad 2004; 351: 337-345.
6. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol 1954; 30: 969-977.
7. Kemeny N. Management of liver metastases from colorectal cancer. Oncology 2006; 20: 10.
8. Kemeny NE, Niedzwiecki D, Hollis DR et al. Hepatic arterial infusion vs systemic therapy for hepatic metastases from colorectal cancer: A randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24: 1395-1403.
9. Kemeny N, Conti JA, Cohen A et al. Phase II study of hepatic arterial floxuridine, leucovorin and dexamethoasone for unresectable liver metastases from colorectal cancer. J Clin Oncol 1994; 12: 2288-2295.
10. Kemeny N, Eid A, Stockman J et al. Hepatic arterial infusion of floxuridine and dexamethasone plus high-dose mitomycin C for patients with unresectable hepatic metastases from colorectal carcinoma. J Surg Oncol 2005; 91: 97-101.
11. Kemeny N, Gönen M, Sullivan D et al. Phase I study of hepatic arterial infusion of floxuridine and dexamethasone with systemic irinotecan for unresectable hepatic metastases from colorectal cancer. J Clin Oncol 2001; 19: 2687-2695.
12. Kemeny N, Jarnigan W, Paty P et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23: 4888-4896.
13. Miller R, Siegmund D. Maximally selected rank statistics. Biometrics 1982; 38: 1011-1016.
14. Terstriep S, Grothey A. First- and second-line therapy of metastatic colorectal cancer. Expert Rev Anticancer Ther 2006; 6(6): 921-930.
15. Saltz LB, Lenz HJ, Hochster H et al. Randomized phase II study of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan refractory colorectal cancer. J Clin Oncol 2005; 23: 3508 (Meeting Abstracts.)
16. Fields AL, Rinaldi DA, Henderson CA et al. An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2005; 23: 16S Abstr 3583.